Trial Profile
Phase 1B Trial With Unesbulin in High-Grade Serous Ovarian Cancer: a Targeted Approach Toward Chemoresistant Stem-Like Cancer Cells
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Unesbulin (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 21 Dec 2023 Planned End Date changed from 1 Feb 2024 to 1 Dec 2024.
- 21 Dec 2023 Planned primary completion date changed from 1 Jan 2024 to 1 Jun 2024.
- 12 Dec 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Jan 2024.